Blood cancer breakthrough? new biomarkers could predict deadly transplant complication

NCT ID NCT07305090

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find biological markers (biomarkers) that can predict how well patients will respond to treatment for a serious complication called gut graft-versus-host disease (GvHD) after a stem cell transplant for blood cancer. Researchers will collect samples from 90 patients aged 12 and older to build a tool that helps doctors personalize treatment. The goal is to improve survival and quality of life by identifying high-risk patients early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    RECRUITING

    Bologna, Bologna, 40138, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••